MPTP-induced behavioural and biochemical deficits: A parametric analysis

  • A. Fredriksson
  • T. Archer
Full Papers


Two experiments were performed to study the parametric effects of long-term administration of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), as a functional model of parkinsonism in mice. The behavioural deficits induced by different doses of MPTP (5, 10, 20, 30 or 40 mg/kg, s.c., each injected on two occasions) at a 3-week or a 3-month treatment-testing interval were evidenced by significant reductions of spontaneous motor activity, from the 10 mg/kg dosages upwards at the 3-week interval and from 30–40 mg/kg at the 3-month interval. Significant dopamine (DA) reductions in the mouse striatum were obtained at these dose levels and intervals. The behavioural deficit of the 40 mg/kg dose (injected on two occasions) and tested at the 3-, 6-, 12-, 24- and 40-week intervals (separate as well as repeated testing groups) indicated marked and relatively comparable reductions of all three parameters of motor activity, locomotion, rearing and total activity. DA depletions were severe at all five test intervals. These results offer functional and neurochemical evidence that MPTP treatment produces permanent damage to the nigrostriatal motor system in mice.


MPTP dose test interval dopamine locomotion rearing total activity mice 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arai N, Misugi K, Goshima Y, Misu Y (1990) Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res 515: 57–63Google Scholar
  2. Archer T, Fredriksson A, Jonsson G, Lewander T, Mohammed AK, Ross SB, Söderberg U (1986) Central noradrenaline depletion antagonizes aspects of damphetamine-induced hyperactivity in the rat. Psychopharmacology 88: 141–146Google Scholar
  3. Burns R, Chiueh C, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci 80: 4546–4550Google Scholar
  4. Close SP, Elliot PJ, Hayes AJ, Marriott AS (1990) Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology 102: 295–300Google Scholar
  5. Duvoisin RC, Heikkela RE, Nicklas WJ, Hess A (1986) Dopaminergic neurotoxicity of MPTP in the mouse: a murine model of parkinsonism. In: Fahn S (ed) Recent developments in Parkinson's disease. Raven Press, New York, pp 147–156Google Scholar
  6. Fredriksson A, Plaznik A, Sundström E, Jonsson G, Archer T (1990) MPTP-induced hypoactivity in mice: reversal by L-Dopa. Pharmacol Toxicol 67: 295–301Google Scholar
  7. Georgiev V, Kambourova T (1991) Behavioural effects of angiotensin II in the mouse following MPTP administration. Gen Pharmacol 22: 625–630Google Scholar
  8. Gupta M, Gupta BK, Thomas R, Bruemmer V, Sladek JR, Felten DL (1986) Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults. Neurosci Lett 70: 326–331Google Scholar
  9. Hallman H, Lange J, Olson L, Strömberg I, Jonsson G (1985) Neurochemical and histochemical characterisation of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on brain catecholamine neurons in the mouse. J Neurochem 44: 117–127Google Scholar
  10. Heikkila RE (1985) Differential neurotoxicty of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources. Eur J Pharmacol 117: 131–133Google Scholar
  11. Heikkila RE, Sieber B-A, Manzino L, Sonsalla PK (1989) Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol 10: 171–183Google Scholar
  12. Hu SC, Chang FW, Sung YJ, Hsu WM, Lee EH (1991) Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the substantia nigra and locus coeruleus in BALB/c mice. J Pharmacol Exp Ther 259: 1379–1387Google Scholar
  13. Irwin I, Langston JW, DeLanney LE (1987) 4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+concentrations and neurotoxicity. Life Sci 40: 731–740Google Scholar
  14. Jonsson G, Hallman H, Mefford I, Adams RN (1980) The use of liquid chromatography with electrochemical detection for the determination of adrenaline and other biogenic in the CNS. In: Fuxe K, Goldstein M, Hökfelt B, Hökfelt T (eds) Central adrenaline neurones. Pergamon Press, Oxford, pp 59–71Google Scholar
  15. Keller R, Oke A, Mefford I, Adams RN (1976) Liquid chromatographic analysis of catacholamines-routine assay for regional brain mapping. Life Sci 19: 995–1004Google Scholar
  16. Kirk RE (1968) Experimental design: procedures for the behavioural sciences. Brooks/ Cole, Belmont CaGoogle Scholar
  17. Lange KW (1990) Behavioural effects and supersensitivity in the rat following intranigral MPTP and MPP+ administration. Eur J Pharmacol 175: 57–61Google Scholar
  18. Lange KW, Löschmann PA, Wachtel H, Horowski H, Jahnig P, Jenner P, Marsden CD (1992) Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. Eur J Pharmacol 212: 247–252Google Scholar
  19. Langston JW (1985) MPTP neurotoxicity: an overview and characterisation of phases of toxicity. Life Sci 36: 201–206Google Scholar
  20. Langston JW, Langston EB, Irwin I (1984) MPTP-induced parkinsonism in human and non-human primates — Clinical and experimental aspects. Acta Neurol Scand 70 [Suppl 100]: 49–54Google Scholar
  21. Ricaurte GA, DeLanney LE, Irwin I, Langston JW (1987) Older dopaminergic neurons do not recover from the effects of MPTP: Neuropharmacology 26: 97–99Google Scholar
  22. Ricaurte GA, Irwin I, Forno LS, DeLanney LE, Langston EB, Langston JW (1987) Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res 403: 43–51Google Scholar
  23. Rose S, Nomoto M, Jackson EA, Gibb WR, Jaehnig P, Jenner P, Marsden CD (1993) Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. Eur J Pharmacol 230: 177–185Google Scholar
  24. Selby G (1968) Parkinson's disease. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology. North-Holland, Amsterdam, pp 173–211Google Scholar
  25. Sershen H, Mason MF, Hashim A, Lajtha A (1985) Effect of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on age related changes in dopamine turnover and transport function in the mouse striatum. Eur J Pharmacol 113: 135–136Google Scholar
  26. Sonsalla PK, Heikkila RE (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 129: 339–345Google Scholar
  27. Sundström E, Fredriksson A, Archer T (1990) Chronic neurochemical and behavioural changes in MPTP-lesioned C57 BL/6 mice: a model for Parkinson's disease. Brain Res 528: 181–188Google Scholar
  28. Sundström E, Goldstein M, Jonsson G (1986) Uptake inhibition protects nigrostriatal dopamine neurons from the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPP+) in mice. Eur J Pharmacol 131: 289–292Google Scholar
  29. Sundström E, Strömberg I, Tsutsumi T, Olson L, Jonsson G (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57 BL/6 mice. Comparison with three other strains of mice. Brain Res 405: 26–38Google Scholar
  30. Takada M, Li ZK, Hattori T (1987) Intracerebral MPTP injections in the rat cause cell loss in the substantia nigra, ventral tegmental area and dorsal raphe. Neurosci Lett 78: 145–150Google Scholar
  31. Tsai YF, Tsai HW, Tai MY, Lu KS (1991) Age-related changes in locomotor behaviour induced by MPTP in rats. Neurosci Lett 129: 153–155Google Scholar
  32. Walsh SL, Wagner GC (1989) Age-dependent effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): correlation with monoamine oxidase-B. Synapse 3: 308–314Google Scholar
  33. Weihmuller FB, Hadjiconstantinou M, Bruno JP (1989) Dissociation between biochemical and behavioural recovery in MPTP-treated mice. Pharmacol Biochem Behav 34: 113–117Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • A. Fredriksson
    • 1
  • T. Archer
    • 2
  1. 1.Department of ToxicologyUppsala UniversityUppsalaSweden
  2. 2.Department of PsychologyUniversity of GöteborgGöteborgSweden

Personalised recommendations